pocketful logo
Dr Lal Pathlabs Ltd logo

Dr Lal Pathlabs Ltd

NSE: LALPATHLAB BSE: 539524

₹1404.70

(1.92%)

Sun, 15 Mar 2026, 04:42 pm

mtf coin illustrationMTF 5x

Dr Lal Pathlabs Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    22702.87

  • Net Profit

    492.25

  • P/B

    9.53

  • Sector P/E

    54.62

  • P/E

    42.52

  • EV/EBITDA

    25.39

  • Debt/Equity (Industry)

    0.18

  • Interest Cover (Industry)

    12.11

  • ROCE (Industry)

    17.65

  • RONW (Industry)

    14.80

  • ROE

    24.48

  • ROCE

    29.23

  • Debt/Equity

    0.10

  • EPS (TTM)

    32.76

  • Dividend Yield

    0.88

  • Book Value

    142.51

  • Interest Cover

    29.01

Analysis

all

thumbs up icon

Pros

  • Dividends paid are well covered by earnings (2.3x coverage).
  • Dividends after 3 years are expected to be well covered by earnings (3.9x coverage).
  • Dr. Lal PathLabs's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Dr. Lal PathLabs's earnings are expected to increase by more than the low risk growth rate in 3 years time.
  • Dr. Lal PathLabs is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
thumbs up icon

Cons

  • Dividend payments have increased, but Dr. Lal PathLabs only paid a dividend in the past 4 years.
  • Whilst dividend payments have been stable, Dr. Lal PathLabs has been paying a dividend for less than 10 years.
  • Dr. Lal PathLabs's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Dr. Lal PathLabs's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Dr. Lal PathLabs is expected to increase but not above the 50% threshold in 2 years time.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters53.2253.2253.7953.9153.91
FII20.2921.8621.6823.9126.82
DII19.2118.4917.9116.0813.17
Public7.286.446.626.106.11
Government0.010000

Read More

Technical Analysis

RSI

41.36

MACD

-13.81

50 DMA

1412.58

200 DMA

1502.99

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1633.801523.101461.501412.401350.801301.701191.00
Fibonacci1523.101480.811454.691412.401370.111343.991301.70
Camarilla1430.341420.201410.051412.401389.751379.611369.46

Pivots Level: Classic

R3

+221.40

1633.80

R2

+110.70

1523.10

R1

+49.10

1461.50

1412.40
1412.40
Pivot Point
LTP: 1355.10

S1

-61.60

1350.80

S2

-110.70

1301.70

S3

-221.40

1191.00

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1378.06

  • 20-EMA

    1389.11

  • 30-EMA

    1397.66

  • 50-EMA

    1414.19

  • 100-EMA

    1447.35

  • 200-EMA

    1466.42

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
30 Jan 2026board-meetingsQuarterly Results
30 Jan 2026dividend₹3.50 Dividend /Share05 Feb 2026
05 Jan 2026dividendInterim Dividend - Rs. - 3.505 Feb 2026
12 Dec 2025bonus1:1 Bonus Issue of Equity Shares12 Dec 2025
19 Nov 2025bonusBonus issue 1:119 Dec 2025
31 Oct 2025board-meetingsQuarterly Results, Half Yearly Results, Interim Dividend, Bonus Issue
31 Oct 2025dividend₹7.00 Dividend /Share07 Nov 2025
07 Oct 2025dividendInterim Dividend - Rs. - 707 Nov 2025
31 Jul 2025dividend₹6.00 Dividend /Share06 Aug 2025
06 Jul 2025dividendInterim Dividend - Rs. - 606 Aug 2025

Read More

Peer Comparison

Dr Lal Pathlabs Ltd logo

Dr Lal Pathlabs Ltd

Narayana Hrudayalaya Ltd logo

Narayana Hrudayalaya Ltd

Aster DM Healthcare Ltd logo

Aster DM Healthcare Ltd

Max Healthcare Institute Ltd logo

Max Healthcare Institute Ltd

Apollo Hospitals Enterprise Ltd logo

Apollo Hospitals Enterprise Ltd

Fortis Healthcare Ltd logo

Fortis Healthcare Ltd

Read More

Dr Lal Pathlabs Ltd About

Dr. Lal PathLabs is engaged in the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations.

Industry

Healthcare

Founded

1995

Headquarters

CEO

Arvind Lal

Employees

Contact

Website icon

Website

http://www.lalpathlabs.com

Email icon

Email

cs@lalpathlabs.com

Phone icon

Phone

91-011-3024 4149

Location icon

Location

E-2 Block Sector 18, Rohini, New Delhi, New Delhi, 110085

Read More

Dr Lal Pathlabs Ltd Company History

YearHistory
2017
  • Dr Lal PathLabs is Amalgameted with Ria and Pathology Private Limited
2018
  • Amalgamation of Shree Computerised Pathology Laboratory, Modern Diagnostics & Modern Lab
2021
  • Dr Lal PathLabs Launches Bangalore Reference Laboratory.
2023
  • NCLT has given approval for Amalgamation between Dr. Lal PathLabs Limited and APL Institute of Clinical Laboratory & Research Private Limited.
2024
  • NCLT, Allahabad Bench sanctioned the Scheme of Amalgamation between two Subsidiary Companies of Dr. Lal PathLabs Limited.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
MULTI-MANAGER ICVCSell4349432997.1106 Jan 2025
SANJEEVINI INVESTMENT HOLDINGSSell42249484015 May 2018
WAGNER LIMITEDSell1012870730.0224 Oct 2017
FRANKLIN TEMPLETON MUTUAL FUNDBuy1048473729.9424 Oct 2017
WAGNER LIMITEDSell75000078029 Aug 2017
WAGNER LIMITEDSell1200000780.7230 Jun 2017
WAGNER LIMITEDSell900000780.2630 Jun 2017
WESTBRIDGE CROSSOVER FUND LLCSell550100950.0217 Mar 2017
WESTBRIDGE CROSSOVER FUND LLCSell1291920950.2701 Mar 2017
WAGNER LIMITEDSell12252601000.3815 Feb 2017

Read More

Dr Lal Pathlabs Ltd News

Dr. Lal PathLabs Completes Subsidiary Liquidation

Dr. Lal PathLabs receives NCLT approval for voluntary liquidation of wholly owned subsidiary Suburban Diagnostics, completing business consolidation process initiated in March 2025.

10 Mar 2026

co actions results

Dr Lal PathLabs Q3 Net Profit Drops 6.4% YoY

Dr Lal PathLabs reported consolidated net profit of ₹905 million in Q3, down from ₹967 million in the same quarter last year, reflecting a year-on-year decline of 6.4%.

30 Jan 2026

co actions results

Dr. Lal PathLabs Board to Meet Jan 30 for Q3 Results

Dr. Lal PathLabs has scheduled a board meeting on January 30, 2026, to consider Q3FY26 financial results and potential 3rd interim dividend for FY2025-26.

23 Jan 2026

co actions results

Dr. Lal PathLabs Launches SOVAAKA Wellness Centre

Dr. Lal PathLabs unveils SOVAAKA, a next-generation diagnostic experience centre in Gurugram, offering personalized wellness programs with advanced diagnostics, AI-supported imaging, and genetic testing.

06 Jan 2026

stocks

Dr. Lal PathLabs Earnings Call Set for Jan 30, 2026

Dr. Lal PathLabs schedules earnings conference call on January 30, 2026, at 4:00 PM IST to discuss Q3 & 9M FY26 financial and operating performance with investors and analysts.

29 Dec 2025

co actions results

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800